37,183 Shares in Mirum Pharmaceuticals, Inc. $MIRM Acquired by Man Group plc

Man Group plc bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 37,183 shares of the company’s stock, valued at approximately $4,353,000.

Other institutional investors have also recently made changes to their positions in the company. Comerica Bank raised its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares in the last quarter. AQR Capital Management LLC grew its position in Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after buying an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after buying an additional 1,720 shares in the last quarter. Caxton Associates LLP bought a new position in Mirum Pharmaceuticals in the 1st quarter worth about $217,000. Finally, Empowered Funds LLC increased its stake in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after acquiring an additional 5,120 shares during the last quarter.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $97.46 on Monday. The business has a 50-day moving average price of $110.63 and a two-hundred day moving average price of $101.80. Mirum Pharmaceuticals, Inc. has a 12-month low of $63.23 and a 12-month high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The firm has a market cap of $6.33 billion, a P/E ratio of -6.70 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.12) earnings per share. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on MIRM. Evercore reissued an “outperform” rating and set a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Royal Bank Of Canada lowered their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Robert W. Baird set a $123.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. CLSA set a $146.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $137.31.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 20,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at $19,221,046.28. This trade represents a 9.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 103,156 shares of company stock valued at $10,888,362 over the last quarter. 8.32% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.